DOCSLIB.ORG

Roche's Long-Odds Aleglitazar Bet Points to Others Chasing the Cardio

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Roche's Long-Odds Aleglitazar Bet Points to Others Chasing the Cardio July 11, 2013 Roche’s long-odds aleglitazar bet points to others chasing the cardio dream Jacob Plieth Much odder than the failure and discontinuation yesterday of Roche’s aleglitazar was the fact that the diabetes project was in such a huge phase III programme to begin with. Aleglitazar was one of the few surviving members of the so-called “glitazar” class, which had largely been written off years ago. Yet it featured as one of 12 antidiabetics being studied in large cardiovascular trials, and its failure turns the spotlight on Takeda’s DPP-IV inhibitor Nesina, the next candidate with a shot at becoming the first diabetes drug to show a cardiovascular benefit (see table). Elusive goal The ability to boast a positive effect on cardiovascular outcomes would be a boon for any diabetes drug’s label, but demonstrating such a benefit has proved elusive. Long-term cardiovascular studies with DPP-IV inhibitors, GLP-1 agonists and SGLT2 inhibitors are ongoing – several to fulfil post-marketing commitments – in more than 80,000 patients. There is anecdotal evidence suggesting that several drug classes improve cardiovascular outcomes, and retrospective analyses have also borne this out. But, although some 70% of people with diabetes die from heart disease and diabetes drugs clearly have glucose-lowering effects, no prospectively designed phase III trial has yet shown any antidiabetic to reduce cardiovascular risk. Plenty are still hoping, even if the primary aim is to rule out risk. Most recently AstraZeneca and Bristol-Myers Squibb unveiled the results of a 16,500-patient study of their DPP-IV inhibitor Onglyza, showing neither an increase nor a reduction in cardiovascular risk (Move along, nothing to see here: Onglyza Savor trial result leaves diabetes world unrocked, June 19, 2013). Study Drug Company Patients Completion Trial ID Status US Status EU name DPP-IV inhibitors Onglyza AstraZeneca/Bristol Savor 16,500 completed NCT01107886 marketed marketed Nesina Takeda Examine 5,384 June 2013 NCT00968708 marketed filed Januvia Merck & Co Tecos 14,000 Dec 2014 NCT00790205 marketed marketed Tradjenta Lilly/Boehringer Carolina 6,000 Sep 2018 NCT01243424 marketed marketed GLP-1 agonists Lyxumia Sanofi Elixa 6,000 Sep 2014 NCT01147250 filed marketed Victoza Novo Nordisk Leader 9,340 Jan 2016 NCT01179048 marketed marketed Bydureon AstraZeneca/Bristol Exscel 9,500 Mar 2017 NCT01144338 marketed marketed dulaglutide Lilly Rewind 9,622 Apr 2019 NCT01394952 phase III phase III SGLT2 inhibitors Boehringer empagliflozin (none) 7,000 Mar 2018 NCT01131676 filed filed Ingelheim Invokana Johnson & Johnson Canvas 4,330 Jun 2018 NCT01032629 marketed filed Forxiga AstraZeneca/Bristol Declare 17,150 Apr 2019 NCT01730534 phase III marketed PPAR agonists stopped aleglitazar Roche Alecardio 7,227 NCT01042769 discontinued discontinued early aleglitazar Roche (none) 19,000 discontinued NCT01715818 discontinued discontinued But Onglyza and most of the other studied agents are already approved for treating diabetes, and a market enlargement strategy has clear logic. Not so for aleglitazar, and Roche’s move to begin a 19,000-patient cardiovascular trial before it had seen any significant phase III data can clearly be questioned. After all, glitazars – molecules with dual agonist action at PPAR alpha and gamma – were seen as a busted flush since the 2006 discontinuations of Bristol-Myers Squibb’s muraglitazar and AstraZeneca’s tesaglitazar. Perhaps the Swiss company simply took the view that for a member of such a beleaguered drug class to make it it had to move fast or lose any chance of success. In any case, all studies of aleglitazar are now being wound down; this includes the Alecardio trial, which formally was the one that failed a futility analysis yesterday, and the huge cardiovascular study that began recruitment in December (Aleglitazar failure will have little impact on booming diabetes market, July 10, 2013). It is not known how many of the 19,000 patients had been enrolled so far. While some have suggested that the muraglitazar failure has a read-across to the related “glitazones” – agents that act preferentially at PPAR gamma – this is likely to be of little more than academic interest. Glitazones, like GlaxoSmithKline’s Avandia and Takeda’s Actos, are insignificant contributors to the current diabetes market. It is, however, interesting that another PPAR agonist threw up a safety signal shortly after the FDA voted to ease restrictions on Avandia’s label, and could lead to criticism of the US regulator’s attempt to clear its name in the oversight of the Glaxo drug. Cardiovascular safety Of course, the issue with Avandia was cardiovascular; that drug’s Record study attempted to address this, and ultimately showed no differences between Avandia and active control for cardiovascular death, myocardial infarction or stroke. While other pharma companies carrying out long-term studies are hoping to show a cardiovascular benefit, the ability to demonstrate a statistically robust lack of increase of risk is equally important. And the sheer size of the populations studied could also be handy in elucidating other factors – such as the pancreatitis risk that has clouded DPP-IV inhibitors and GLP-1 agonists. For some, results will be a long time coming, and most of the studies do not read out until towards the end of the decade. For instance, none of the SGLT2 inhibitors – this class has been marred by genitourinary infections – will yield results before 2018. Nesina’s trial, also measuring occurrence of a composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke, has been completed and could read out late this year. Much more important will be the Tecos study of Januvia, Merck & Co’s $4bn blockbuster, which could generate data next year. The demonstration of a cardiovascular benefit could be a big advantage on a diabetes drug’s label, and perhaps sooner or later one of the companies will get lucky. Roche’s gamble with aleglitazar shows just how important big pharma still thinks this is. To contact the writer of this story email Jacob Plieth in London at [email protected] or follow @JacobEPVantage on Twitter More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..
Load more

Recommended publications
  • Combination Treatment with Pioglitazone and Fenofibrate
    179 Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats Rana Samadfam, Malaika Awori, Agnes Be´nardeau1, Frieder Bauss2, Elena Sebokova1, Matthew Wright1 and Susan Y Smith Charles River Laboratories, 22022 Transcanadienne, Senneville, Montre´al, Que´bec, Canada H9X 3R3 1F. Hoffmann-La Roche AG, Basel, CH-4070 Switzerland 2Roche Diagnostics GmbH, Penzberg, DE-82377 Germany (Correspondence should be addressed to S Y Smith; Email: [email protected]) Abstract Peroxisome proliferator-activated receptor (PPAR) g ago- mineral content (w45%) and bone mineral density (BMD; nists, such as pioglitazone (Pio), improve glycemia and lipid w60%) at the lumbar spine. Similar effects of treatments were profile but are associated with bone loss and fracture risk. Data observed at the femur, most notably at sites rich in trabecular regarding bone effects of PPARa agonists (including bone. At the proximal tibial metaphysis, concomitant fenofibrate (Feno)) are limited, although animal studies treatment with PioCFeno prevented Pio exacerbation of suggest that Feno may increase bone mass. This study ovariectomy-induced loss of trabecular bone, resulting in investigated the effects of a 13-week oral combination BMD values in the PioCFeno group comparable to OVX treatment with Pio (10 mg/kg per day)CFeno (25 mg/kg controls. Discontinuation of Pio or Feno treatment of per day) on body composition and bone mass parameters OVX rats was associated with partial reversal of effects on compared with Pio or Feno alone in adult ovariectomized bone loss or bone mass gain, respectively, while values in the (OVX) rats, with a 4-week bone depletion period, followed PioCFeno group remained comparable to OVX controls.
    [Show full text]
  • Comparative Transcriptional Network Modeling of Three PPAR-A/C Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes
    Comparative Transcriptional Network Modeling of Three PPAR-a/c Co-Agonists Reveals Distinct Metabolic Gene Signatures in Primary Human Hepatocytes Rene´e Deehan1, Pia Maerz-Weiss2, Natalie L. Catlett1, Guido Steiner2, Ben Wong1, Matthew B. Wright2*, Gil Blander1¤a, Keith O. Elliston1¤b, William Ladd1, Maria Bobadilla2, Jacques Mizrahi2, Carolina Haefliger2, Alan Edgar{2 1 Selventa, Cambridge, Massachusetts, United States of America, 2 F. Hoffmann-La Roche AG, Basel, Switzerland Abstract Aims: To compare the molecular and biologic signatures of a balanced dual peroxisome proliferator-activated receptor (PPAR)-a/c agonist, aleglitazar, with tesaglitazar (a dual PPAR-a/c agonist) or a combination of pioglitazone (Pio; PPAR-c agonist) and fenofibrate (Feno; PPAR-a agonist) in human hepatocytes. Methods and Results: Gene expression microarray profiles were obtained from primary human hepatocytes treated with EC50-aligned low, medium and high concentrations of the three treatments. A systems biology approach, Causal Network Modeling, was used to model the data to infer upstream molecular mechanisms that may explain the observed changes in gene expression. Aleglitazar, tesaglitazar and Pio/Feno each induced unique transcriptional signatures, despite comparable core PPAR signaling. Although all treatments inferred qualitatively similar PPAR-a signaling, aleglitazar was inferred to have greater effects on high- and low-density lipoprotein cholesterol levels than tesaglitazar and Pio/Feno, due to a greater number of gene expression changes in pathways related to high-density and low-density lipoprotein metabolism. Distinct transcriptional and biologic signatures were also inferred for stress responses, which appeared to be less affected by aleglitazar than the comparators. In particular, Pio/Feno was inferred to increase NFE2L2 activity, a key component of the stress response pathway, while aleglitazar had no significant effect.
    [Show full text]
  • The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
    International Journal of Molecular Sciences Review The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development Fan Hong 1,2, Pengfei Xu 1,*,† and Yonggong Zhai 1,2,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China * Correspondence: [email protected] (P.X.); [email protected] (Y.Z.); Tel.: +86-156-005-60991 (P.X.); +86-10-5880-6656 (Y.Z.) † Current address: Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA. Received: 22 June 2018; Accepted: 24 July 2018; Published: 27 July 2018 Abstract: Peroxisome proliferator-activated receptors (PPARs) are a well-known pharmacological target for the treatment of multiple diseases, including diabetes mellitus, dyslipidemia, cardiovascular diseases and even primary biliary cholangitis, gout, cancer, Alzheimer’s disease and ulcerative colitis. The three PPAR isoforms (α, β/δ and γ) have emerged as integrators of glucose and lipid metabolic signaling networks. Typically, PPARα is activated by fibrates, which are commonly used therapeutic agents in the treatment of dyslipidemia. The pharmacological activators of PPARγ include thiazolidinediones (TZDs), which are insulin sensitizers used in the treatment of type 2 diabetes mellitus (T2DM), despite some drawbacks. In this review, we summarize 84 types of PPAR synthetic ligands introduced to date for the treatment of metabolic and other diseases and provide a comprehensive analysis of the current applications and problems of these ligands in clinical drug discovery and development.
    [Show full text]
  • Insulin Secretion Volume of Cells
    Société Médicale des Hôpitaux de Paris Le diabète quels enjeux ? 14 janvier 2011 DIABETE DE TYPE 2 NOUVELLES PISTES THÉRAPEUTIQUES Alain Ktorza Institut de Recherches Servier (IdRS) THE AIMS OF TREATMENT OF TYPE 2 DIABETES To prevent early death and improve quality of life To prevent micro- and macro vascular complications •Lipid profile •Cardiovascular Optimal glycemic control function •Atherogenes is CURRENT ORAL AGENTS USED IN THE TREATMENT OF TYPE 2 DIABETES THIAZOLIDINEDIONES SULFONYLUREAS INSULIN GLINIDES Pancreas INCRETINES (GLP-1) Gut White adipose tissue METFORMIN Muscle Liver ACARBOSE 6/7 different approaches. No one prevents the progressive deterioration of glycemic control FUNCTIONAL CELL MASS AND TYPE 2 DIABETES Decrease in cell mass in type 2 diabetic patients 40-60% Reduction compared to non diabetic patients Maclean, Ogilvie – 1955, Westermark, Wilander – 1978, Saito, et al, 1978,,,pp,1979, Klöppel, et al – 1985,,, Butler, et al – 2003,,, Yoon, et al – 2003, Deng et al - 2004 … Functionnal cell mass Insulin synthesis Number of cells Insulin secretion Volume of cells DihfilDecrease in the functional cell mass Progressive damage of glycemic control in type 2 diabetic patients POSSIBLE MECANISM OF CELL FAILURE IN TYPE 2 DIABETES Insulin resistance (b(obes ity, over fee ding, ph ysi cal li inacti tiitvity, geneti tifc fact ors?) N O -cell overstimulation Primary factors of R -cell stress dysfunction (genetic) M O H G Compensatory increase of Y L functional cell mass P Y E C R « Robust » cell « Susceptible » cell A
    [Show full text]
  • Beacon of Hope Summer 2013 • No. 115 Some Folks, When They Want To
    Beacon of Hope Summer 2013 • No. 115 Some folks, when they want to escape life's stresses, go to Cancun or Bali or Virginia Beach. I found my oasis in downtown Boston. A few weeks ago I took part in BEACON HILL, an outpatient trial for the bihormonal bionic pancreas developed by researchers at Mass General and Boston University. The study participants and I spent five days wearing a system that continuously monitored our glucose levels, delivering insulin or glucagon as necessary to keep us in the normal glucose range for as long as possible, with no effort from us (seriously). I pressed a button to tell the system when I was eating and whether the meal was bigger, larger, or similar relative to my typical schedule, but I didn't count any carbs or consult any nutrition facts or calculate any insulin doses. I looked at my continuous glucose monitor, but I didn't worry about going hypoglycemic or spending hours above 200 mg/dl or waking up at 4 AM with my blood sugar out of whack. In short, I knew that I still had diabetes, but I have never felt so carefree - so much like my 17- year-old, pre-diagnosis self - as during that week of glucose autopilot. I should clarify that the bionic pancreas is still a prototype and that a lot of challenges must still be overcome - especially if the researchers are to meet their ambitious goal of commercial launch in 2017. The system's effectiveness must be proven in longer and larger trials, a stabilized liquid glucagon must be developed, and a bihormonal pump must be built (that is, a pump that delivers both insulin and glucagon).
    [Show full text]
  • BM17864 CSR Synopsis
    SYNOPSIS OF RESEARCH REPORT (PROTOCOL BM17864) (FOR NATIONAL AUTHORITY USE ONLY) COMPANY: NAME OF FINISHED PRODUCT: NAME OF ACTIVE SUBSTANCE(S): TITLE OF THE STUDY / REPORT No. / A randomized, double-blind, parallel group, placebo-controlled DATE OF REPORT (with open-label active comparator arm), dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of aleglitazar (dual PPAR α/γ agonist) therapy when administered to patients with type 2 diabetes mellitus. November 2008 INVESTIGATORS / CENTERS AND Multicenter study involving 47 centers in 7 countries: COUNTRIES USA (14 centers), Mexico (11 centers), Russia (7 centers), Italy (6 centers), Romania (5 centers), Serbia (4 centers) and Hong Kong (2 centers) PUBLICATION (REFERENCE) N/A PERIOD OF TRIAL 9 October 2006 – 27 December CLINICAL PHASE II 2007 OBJECTIVES Primary objective: to determine the dose(s) of aleglitazar which are efficacious in improving glycemic control, safe, and tolerable in patients with T2D when administered orally, once daily for 16 weeks compared with placebo Secondary objectives: to explore by a population analysis approach the pharmacokinetics (PK) and exposure-response relationship of aleglitazar in the target patient population; to use active comparator (pioglitazone) data to support the dose selection of aleglitazar for comparative phase 3 studies with model-based simulation, if feasible. STUDY DESIGN Multicenter, randomized, double-blind, parallel group, placebo-controlled study with open-label active comparator arm, comprising six treatment groups: placebo, 4 dose levels of aleglitazar (0.05, 0.15, 0.3 and 0.6 mg) and 45 mg pioglitazone. Patients were stratified according to their disease severity (baseline A1C < 8.5% or ≥ 8.5%) NUMBER OF SUBJECTS Planned: 300 (50 per treatment group) Actual: 332 (55-57 per treatment group) DIAGNOSIS AND MAIN CRITERIA FOR Adult patients with T2D for at least 1 month, either drug-naive or INCLUSION pre-treated with monotherapy or combination therapy (max.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,492.422 B2 Takahashi Et Al
    USOO9492422B2 (12) United States Patent (10) Patent No.: US 9,492.422 B2 Takahashi et al. (45) Date of Patent: Nov. 15, 2016 (54) THERAPEUTIC OR PROPHYLACTIC JP 52-136161 A 11/1977 AGENT FOR DIABETES JP 54-095552 A 7/1979 JP 54-130543. A 10, 1979 JP 55-000313 A 1, 1980 (75) Inventors: Takehiro Takahashi, Kamakura (JP); JP 55-022636 A 2, 1980 Hiroki Kumagai, Kamakura (JP); JP 55-057559 A 4f1980 JP 58-219 162 A 12/1983 Takashi Kadowaki, Tokyo (JP): Naoto JP 59-137445. A 8, 1984 Kubota, Tokyo (JP); Tetsuya Kubota, JP 59-141536 A 8, 1984 Tokyo (JP) JP 59-157050 A 9, 1984 JP 61-030519 A 2, 1986 (73) Assignees: Toray Industries, Inc. (JP); The JP 61-267580 A 11, 1986 JP 62-286924 A 12/1987 University of Tokyo (JP) JP 105.3672 B 11, 1989 JP 2-167227 A 6, 1990 (*) Notice: Subject to any disclaimer, the term of this JP 3-005457 A 1, 1991 patent is extended or adjusted under 35 JP 3-246252 A 11, 1991 U.S.C. 154(b) by 36 days. JP 10-251.146 A 9, 1998 JP 2001-512478 A 8, 2001 JP 2006-199694 A 8, 2006 (21) Appl. No.: 13/509,483 JP 2006-523668 A 10, 2006 JP 2007-191494. A 8, 2007 (22) PCT Filed: Nov. 12, 2010 JP 2007-536229 A 12/2007 JP 2008-530097 A 8, 2008 (86). PCT No.: PCT/UP2010/070185 WO 99.1388.0 A1 3, 1999 WO OOO7992 A1 2, 2000 S 371 (c)(1), WO 02/088084 A1 11, 2002 (2), (4) Date: Jun.
    [Show full text]
  • Comparative Molecular Profiling of the PPAR/ Activator
    MED DOI: 10.1002/cmdc.201100598 Comparative Molecular Profiling of the PPARa/g Activator Aleglitazar: PPAR Selectivity, Activity and Interaction with Cofactors Michel Dietz,[b] Peter Mohr,[c] Bernd Kuhn,[c] Hans Peter Maerki,[c] Peter Hartman,[d] Armin Ruf,[b] Jçrg Benz,[b] Uwe Grether,[c] and Matthew B. Wright*[a] Peroxisome proliferator-activated receptors (PPARs) are zar was evaluated in a head-to-head comparison with other a family of nuclear hormone receptors that control the expres- PPARa, g and d ligands. A comprehensive, 12-concentration sion of genes involved in a variety of physiologic processes, dose–response analysis using a cell-based assay showed alegli- through heterodimerization with retinoid X receptor and com- tazar to be highly potent, with EC50 values of 5 nm and 9 nm plex formation with various cofactors. Drugs or treatment regi- for PPARa and PPARg, respectively. Cofactor recruitment pro- mens that combine the beneficial effects of PPARa and g ago- files confirmed that aleglitazar is a potent and balanced activa- nism present an attractive therapeutic strategy to reduce cardi- tor of PPARa and g. The efficacy and potency of aleglitazar are ovascular risk factors. Aleglitazar is a dual PPARa/g agonist cur- discussed in relation to other dual PPARa/g agonists, in con- rently in phase III clinical development for the treatment of pa- text with the published X-ray crystal structures of both PPARa tients with type 2 diabetes mellitus who recently experienced and g. an acute coronary event. The potency and efficacy of
    [Show full text]
  • 09.Subjectindex ADA 13.Indd
    SUBJECT INDEX (-)-Epigallocatechin-3-gallate 2919-PO Add-on to basal insulin 1102-P Aggressiveness factor 2526-PO 1,5-Anhydroglucitol 928-P Add-on to metformin 1092-P Aging 1284-P, 1396-P, 1399-P, 1797-P, 1966-P, 11 β-HSD 1993-P Add-on to metformin + SU 1082-P 1972-P, 1981-P, 2007-P, 2209-P, 2308-PO, 11beta-HSD, glucocorticosteroids, type 2 diabetes Add-on to pioglitazone 1120-P 2481-PO, 2693-PO, 2697-PO 1128-P Adenine nucleotide translocase 28-OR, 29-OR Aging society 2657-PO 11β-HSD1 1875-P Adenosine A1 receptor 1854-P Agreement 2508-PO SUBJECT INDEX 12(S)-HETE 2057-P Adenovirus, shrna, over expression 340-OR Agrp neurons 1917-P 12/15-Lipoxygenase 2057-P Adherence 652-P, 789-P, 802-P, 814-P, 821-P, 857-P, AICAR 1815-P 12-Lipoxygenase 338-OR 889-P, 894-P, 1227-P, 1259-P, 1423-P, 2504-PO Akita 1643-P 14-3-3 142-OR Adhesive capsulitis 2887-PO Akt 25-OR 18FDG PET 2026-P Adipocyte 100-OR, 1644-P, 1748-P, 1748-P, 1749-P, Akt mediated signaling pathway 2321-PO 18F-TTCO-cys40-exendin-4 2163-P 1751-P, 1752-P, 1755-P, 1756-P, 1758-P, 1761-P, Akt, glucose uptake 1802-P 1-h plasma glucose 1457-P, 2808-PO 1763-P, 1765-P, 1769-P, 1769-P, 2056-P, 2943-PO Akt/GSK3 signaling pathway 488-P 25(OH)D 679-P Adipocyte differentiation 144-OR, 1745-P, 1745-P, Akt2 1818-P 25-hydroxivitamin D 2035-P 2013-P Alanine 1916-P 26S Proteasomes 498-P Adipocyte fatty acid-binding protein 2003-P Alanine aminotransferase 1460-P, 2860-PO 2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid Adipocyte precursor cells 2081-P Alaska native people 183-OR 2079-P Adipocytes 94-OR, 95-OR,
    [Show full text]
  • Assessment of Cardiovascular Effects of Non-Insulin Blood-Glucose-Lowering Agents Nelly Herrera Comoglio
    Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents Nelly Herrera Comoglio To cite this version: Nelly Herrera Comoglio. Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents. Human health and pathology. Université de Bordeaux, 2019. English. NNT : 2019BORD0355. tel-02969556 HAL Id: tel-02969556 https://tel.archives-ouvertes.fr/tel-02969556 Submitted on 16 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE PRÉSENTÉE POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX ÉCOLE DOCTORALE SPÉCIALITÉ PHARMACOÉPIDEMIOLOGIE Option Pharmaco-épidémiologie, pharmaco-vigilance Par Nelly Raquel HERRERA COMOGLIO TITRE : ÉVÉNEMENTS CARDIOVASCULAIRES MAJEURS ET MORTALITÉ EN PATIENTS TRAITÉS AVEC DES HYPOGLYCÉMIANTS NON INSULINIQUES Étude de cohortes basée sur une population de Catalogne, Espagne Sous la direction de : Xavier VIDAL GUITART Soutenue le 17 Décembre 2019 Membres du jury : Mme. AGUSTI ESCASANY, Antonia Prof. Fundacio Institut Catala de Farmacologia Président, rapporteur Mme. BOSCH Montserrat Prof. Associée Fundacio Institut Catala de Farmacologia Examinateur M. SALVO, Francesco Prof. Université de Bordeaux Examinateur Titre : ÉVÉNEMENTS CARDIOVASCULAIRES MAJEURS ET MORTALITÉ EN PATIENTS TRAITÉS AVEC DES HYPOGLYCÉMIANTS NON INSULINIQUES Étude de cohortes basée sur une population de Catalogne, Espagne Résumé : Le diabète mellitus Type 2 (DMT2) est une maladie chronique et progressive causée par multiples facteurs.
    [Show full text]
  • Oral Anti-Diabetic Agents-Review and Updates
    British Journal of Medicine & Medical Research 5(2): 134-159, 2015, Article no.BJMMR.2015.016 ISSN: 2231-0614 SCIENCEDOMAIN international www.sciencedomain.org Oral Anti-Diabetic Agents-Review and Updates Patience O. Osadebe1, Estella U. Odoh2 and Philip F. Uzor1* 1Department of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, 410001, Nigeria. 2Department of Pharmacognosy and Environmental Medicine, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, 410001, Nigeria. Authors’ contributions Author POO designed the study, participated in the literature search. Author EUO participated in designing the work and in searching the literature. Author PFU participated in designing the work, searched the literature and wrote the first draft of the manuscript. All authors read and approved the final manuscript. Article Information DOI:10.9734/BJMMR/2015/8764 Editor(s): (1) Mohamed Essa, Department of Food Science and Nutrition, Sultan Qaboos University, Oman. (2) Franciszek Burdan, Experimental Teratology Unit, Human Anatomy Department, Medical University of Lublin, Poland and Radiology Department, St. John’s Cancer Center, Poland. Reviewers: (1) Anonymous, Bushehr University of Medical, Iran. (2) Anonymous, Tehran University of Medical Sciences, Iran. (3) Anonymous, King Fahad Armed Forces Hospital, Saudi Arabia. (4) Awadhesh Kumar Sharma, Mlb Medical College, Jhansi, UP, India. Peer review History: http://www.sciencedomain.org/review-history.php?iid=661&id=12&aid=5985 Received 30th December 2013 Review Article Accepted 13th March 2014 Published 8th September 2014 ABSTRACT Diabetes is a chronic metabolic disorder with high mortality rate and with defects in multiple biological systems. Two major types of diabetes are recognized, type 1 and 2 with type 2 diabetes (T2D) being by far the more prevalent type.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]